49th week of 2015 patent applcation highlights part 24 |
Patent application number | Title | Published |
20150344413 | COMPOUNDS FOR THE TREATMENT OF SEIZURES AND OTHER CENTRAL NERVOUS SYSTEM DISORDERS AND CONDITIONS - The present application relates to novel compounds comprising a moiety that leads to the metabolic production of ketones bonded to a ketone-potentiated anti-epileptic drug, compositions comprising these compounds, and their use, for example for the treatment of epilepsy, and other CNS diseases, disorders or conditions. In particular, the present application includes compounds of Formula I, and compositions and uses thereof: | 2015-12-03 |
20150344414 | COPOLYMER, AND METHOD FOR PREPARING A MONOMER USED TO FORM THE COPOLYMER - A copolymer, and a method for preparing a monomer used to form the copolymer are provided. The copolymer is a reaction product of a first monomer and a second monomer. In particular, the first monomer has a structure represented by Formula (I), and the second monomer has a structure represented by Formula (II), Formula (III), or Formula (IV) | 2015-12-03 |
20150344415 | SHIKONIN, ALKANNIN; AND RACEMIC PARENT NUCLEUS CABONYL OXIME DERIVATIVES AND APPLICATIONS THEREOF - A structural formula of a shikonin naphthazarin parent nucleus hydroxyl methylation carbonyl oxime derivative is shown in Formula (I) or (II); a structural formula of an alkannin naphthazarin parent nucleus hydroxyl methylation carbonyl oxime derivative is shown in Formula (III) or (IV); and a structural formula of a racemic shikonin naphthazarin parent nucleus hydroxyl methylation carbonyl oxime derivative is shown in Formula (V) or (VI), wherein R1 is alkane, olefin, arene, or substituting arene comprising 1 to 6 carbon atoms; and R2 is alkane, olefin, arene, or substituting arene comprising 1 to 6 carbon atoms or is H. The shikonin, alkannin, and racemic oxime derivatives of the present invention have novel structures, and in-vitro experiments show that the present invention has good growth inhibitory activity against tumor cells and can be used in tumor treatment. | 2015-12-03 |
20150344416 | CROSS METATHESIS PROCESS - A process for the synthesis of an unsaturated product by cross metathesis between a first unsaturated compound having at least 8 carbon atoms and a second unsaturated compound having less than 8 carbon atoms, the first unsaturated compound being capable of producing an unsaturated coproduct comprising more than 14 carbon atoms, by homometathesis, said process including at least one production phase which includes: feeding a reactor with the first unsaturated compound; feeding the reactor with the second unsaturated compound; feeding the reactor with at least a first metathesis catalysts, then feeding the reactor with at least a second metathesis catalyst; withdrawing a product stream arising from the reactor; the turnover number of the first catalyst being higher than the turnover number of the second catalyst so as to achieve the same target degree of conversion of the first unsaturated compound. | 2015-12-03 |
20150344417 | WATER FEED METHODS TO CONTROL MW DISTRIBUTION AND BYPRODUCTS OF THE CARBAMYLATION OF UREA - The present invention provides methods for making a polycarbamate by feeding a) a urea in fluid form into a reaction medium containing b) an alkyd polyol, such as a short or med oil alkyd polyol to form a reaction mixture and then carbamylating the alkyd polyol by heating the reaction mixture while feeding water in to the reaction mixture, preferably, in the presence of one or more c) carbamylation catalysts. The polycarbamate of the present invention when combined with a polyaldehyde or an acetal or hemiacetal thereof as a second component makes a multicomponent composition that is substantially isocyanate-free, and cures at a temperature of from 0° C. to less than 80° C. to form a crosslinked polyurethane. | 2015-12-03 |
20150344418 | HIGH PURITY DIPHENYL SULFONE, PREPARATION AND USE THEREOF FOR THE PREPARATION OF A POLY(ARYLETHERKETONE) - The presence of certain impurities in diphenyl sulfone have a deleterious effect on the properties of the poly(aryletherketone)s produced therein, including one or more of color, melt stability, molecular weight, crystallinity, etc. and here identify those impurities and provide processes for the recovery of the diphenyl sulfone. | 2015-12-03 |
20150344419 | PROPIONIC ACIDS, PROPIONIC ACID ESTERS, AND RELATED COMPOUNDS - The invention relates to compounds of the following formula: | 2015-12-03 |
20150344420 | PACLITAXEL ENHANCER COMPOUNDS - Disclosed is a compound represented by the Structural Formula (I): | 2015-12-03 |
20150344421 | Versatile and Functionalised Intermediates for the Synthesis of Vitamin D and Novel Vitamin D Derivatives - Novel intermediates for the complete synthesis of vitamin D are provided that allow a great versatility of functional groups in the final vitamin derivatives. Vitamin derivatives that are epimeric in position 3 and vitamin derivatives with a wide range of functionalities in position 18, including compounds with isotopic labelling are provided. | 2015-12-03 |
20150344422 | Pyrrole Derivatives as Alpha 7 NACHR Modulators - Disclosed are compounds of the Formula (I), wherein R | 2015-12-03 |
20150344423 | CARBOXAMIDE OR SULFONAMIDE SUBSTITUTED NITROGEN-CONTAINING 5-MEMBERED HETEROCYCLES AS MODULATORS FOR THE ORPHAN NUCLEAR RECEPTOR ROR GAMMA - The invention provides modulators for the orphan nuclear receptor RORy and methods for treating RORy mediated diseases by administering these novel RORy modulators to a human or a mammal in need thereof. Specifically, the present invention provides carboxamide containing cyclic compounds of Formula (1) to Formula (5) and the enantiomers, diastereomers, tautomers, /V-oxides, solvates and pharmaceutically acceptable salts thereof. | 2015-12-03 |
20150344424 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE - Compounds having a structure of Structure I: | 2015-12-03 |
20150344425 | INDOLE CARBOXAMIDE DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS - The invention relates to indole carboxamide derivatives of formula (I), | 2015-12-03 |
20150344426 | COMPOUNDS AND THERAPEUTIC USES THEREOF - The invention relates to compounds, pharmaceutical compositions and methods useful for treating cancer, systemic or chronic inflammation, rheumatoid arthritis, diabetes, obesity, T-cell mediated autoimmune disease, ischemia, and other complications associated with these diseases and disorders. | 2015-12-03 |
20150344427 | 1,4-PYRIDONE COMPOUNDS - The present invention relates to 1,4-pyridone compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2015-12-03 |
20150344428 | Catalytic Manufacturing Method for Imine Having No Substituent Group on the Nitrogen, and Use for the Imine Produced - The present invention relates to a method for manufacturing an imine having no substituent group on the nitrogen by using, as a catalyst, a metal complex on an organic azide compound, and more specifically relates to a method in which a metal-complex catalyst is used to produce, from an organic azide having an alpha-hydrogen, an imine having no substituent group on the nitrogen via a continuous nitrogen removal and 1,2-hydrogen transfer reaction. The imine having no substituent group on the nitrogen manufactured by means of the method of the present invention can synthesise diverse coupling products comprising amine compounds by means of reactions with diverse nucleophiles. | 2015-12-03 |
20150344429 | PYRIDINE-2-AMIDES USEFUL AS CB2 AGONISTS - The invention relates to a compound of formula (I) wherein R | 2015-12-03 |
20150344430 | METHODS OF LOWERING PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) - The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases. | 2015-12-03 |
20150344431 | METHOD FOR PRODUCING PURIFIED AMINE COMPOUND - A method for producing a purified amine compound represented by the formula (1), including: step (A) of reacting a crude form of the amine compound represented by the formula (1) with a hydrogen halide in the presence of water and an organic solvent insoluble in water; step (B) of separating a phase in which a hydrogen halide salt of the amine compound represented by the formula (1) produced in step (A) is dissolved from the other phase(es); step (C) of precipitating the hydrogen halide salt of the amine compound represented by the formula (1) from the phase obtained in step (B) in which the hydrogen halide salt of the amine compound represented by the formula (1) is dissolved; and step (D) of isolating the hydrogen halide salt of the amine compound represented by the formula (1) precipitated in step (C), and reacting the salt with a base. | 2015-12-03 |
20150344432 | PERI-CARBINOLS - The present invention is directed to compounds of formula(I): | 2015-12-03 |
20150344433 | PRMT5 INHIBITORS CONTAINING A DIHYDRO- OR TETRAHYDROISOQUINOLINE AND USES THEREOF - Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. | 2015-12-03 |
20150344434 | TETRAHYDRO- AND DIHYDRO-ISOQUINOLINE PRMT5 INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5 mediated disorders are also described. | 2015-12-03 |
20150344435 | PROCESS FOR PREPARATING IVABRADINE HYDROCHLORIDE FORM IV AND METHODS OF TREATMENT OF DISEASE USING IVABRADINE HYDROCHLORIDE FORM IV - Ivabradine hydrochloride Form IV, its pharmaceutical composition, process for its preparation, and its use as therapeutically active ingredient and pharmaceutical compositions containing lvabradine hydrochloride Form IV. | 2015-12-03 |
20150344436 | PKM2 MODULATORS AND METHODS FOR THEIR USE - Compounds having activity as PKM2 activators are disclosed. The compounds have the following structure (I): including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof, wherein R1, R2, R3, R4, R5 and R6 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed. | 2015-12-03 |
20150344437 | PYRAZOLONE DERIVATIVES AS NITROXYL DONORS - The disclosed subject matter provides pyrazolone derivative compounds, pharmaceutical compositions comprising such compounds, kits comprising such compounds, and methods of using such compounds or pharmaceutical compositions. In particular, the disclosed subject matter provides methods of using such compounds or pharmaceutical compositions for treating heart failure. | 2015-12-03 |
20150344438 | METHOD FOR PRODUCING HALOHYDANTOIN COMPOUND AND HALOHYDANTOIN COMPOUND - A method for producing a halohydantoin compound according to the present invention includes the steps of: (a) providing, in a dryer, a composition containing (i) at least one component selected from the group consisting of water, an organic solvent, and elemental halogen and (ii) a halohydantoin compound; and (b) drying the composition under reduced pressure in the dryer, the reduced pressure being reduced to a pressure lower than atmospheric pressure while introducing an inert gas from an outside source into the dryer. | 2015-12-03 |
20150344439 | Convenient Process for the Preparation of Statins - Object of the present invention is an improved process for the preparation of key intermediates for the synthesis of statins. | 2015-12-03 |
20150344440 | Compounds and Methods of Use Thereof for Treating Tumors - The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated with abnormal cell growth, for example, treating or preventing cancer or tumor growth, which methods include administering to a mammal in need thereof a composition comprising a therapeutically or prophylactically effective amount of a compound of the invention or a pharmaceutically acceptable salt thereof. | 2015-12-03 |
20150344441 | SALTS OF AN EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR - The present invention provides a salt form and compositions thereof, which are useful as an inhibitor of EGFR kinases and which exhibits desirable characteristics for the same. | 2015-12-03 |
20150344442 | CYCLIC AMINES AS BROMODOMAIN INHIBITORS - The present disclosure relates to compounds, which are useful for inhibition of BET protein function by binding to bromodomains, and their use in therapy. | 2015-12-03 |
20150344443 | INHIBITORS OF THE USP1/UAF1 DEUBIQUITINASE COMPLEX AND USES THEREOF - Disclosed are inhibitors of the USP1/UAF1 deubiquitinase complex, for example. of formula (I), wherein R | 2015-12-03 |
20150344444 | BET-PROTEIN-INHIBITING DIHYDROXYQUINOXALINONES - The present invention relates to BET protein-inhibitory, especially BRD4-inhibitory, dihydroquinoxalinones of the general formula (I) | 2015-12-03 |
20150344445 | COMPOSITIONS COMPRISING A TRIAZOLE COMPOUND - The present invention relates to compositions comprising, 1) as component I a compound of formula I, as defined in the claims and description, and 2) as component II an active ingredient, selected from the groups A) to O) defined in the claims and description. | 2015-12-03 |
20150344446 | TRIAZOLONE COMPOUNDS AND USES THEREOF - The invention disclosed herein is directed to compounds of Formula I | 2015-12-03 |
20150344447 | NOVEL TRAPS IN THE TREATMENT OF MACULAR DEGENERATION - The present invention is directed to compounds of formula (A): | 2015-12-03 |
20150344448 | Highly Selective Anti-Cancer Agents Targeting Non-Small Cell Lung Cancer and Other Forms of Cancer - Described herein are analogues of 2-methyl-3-(2-ethynylthiazol-4-yl)cyclopent-2-enol and the corresponding ketone 3-(2-ethynylthiazol-4-yl)-2-methylcyclopent-2-enone, the analogues having terminal alkyne groups at the 2-position of the thiazole ring. These drug-like molecules, referred to as CETZOLE compounds, are useful to treat non-small cell lung cancer and other forms of cancer. Methods of making and using the compounds, methods of treating various diseases, pharmaceutical compositions, and kits are also disclosed. | 2015-12-03 |
20150344449 | ANTIBACTERIAL COMPOUNDS - The present invention relates to the following compounds for use in the treatment of a bacterial infection | 2015-12-03 |
20150344450 | SYNTHESIS, STRUCTURE AND USE OF FUNCTIONALIZED NAPHTHALENES - Methods for the synthesis and use of functionalized, substituted naphthalenes are described. The functionalized, substituted naphthalenes display useful properties including liquid crystals and fluorescence properties, such as solvatochromatic fluorescence, with high quantum yields, Stoke's shift, and show emission maxima that are significantly red-shifted. | 2015-12-03 |
20150344451 | PREPARATION METHOD FOR AN IMINE COMPOUND AND REDUCTION METHOD FOR SOLID POWDER OF A CARBAMIC ACID DERIVATIVE - The present application relates to a preparation method for solid powder of a carbamic acid derivative, which includes reacting an amine derivative with carbon dioxide at a temperature in a range of from about −30° C. to about 500° C. and at a pressure in a range of from about 0.3 MPa to about 100 MPa. In addition, the present disclosure relates to a reduction method for solid powder of a carbamic acid derivative to an amine derivative and carbon dioxide, which includes dissolving solid powder of the carbamic acid derivative prepared in a solvent; refluxing the carbamic acid derivative at a temperature in a range of from about 30° C. to about 100° C.; and evaporating the solvent. | 2015-12-03 |
20150344452 | PROCASPASE ACTIVATING COMPOUNDS - Compositions and methods are disclosed in embodiments relating to induction of cell death such as in cancer cells. Compounds and related methods for synthesis and use thereof, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells are disclosed. Compounds are disclosed that have lower neurotoxicity effects than other compounds. | 2015-12-03 |
20150344453 | PROCESS FOR FORMING A PRIMARY, A SECONDARY OR A TERTIARY AMINE VIA A DIRECT AMINATION REACTION - The present invention concerns a process to obtain primary, secondary or tertiary amines, via a direct amination reaction of alcohols in presence of bis(perfluoroalkylsulfonimide) acid or salts thereof catalysts, and derivatives. | 2015-12-03 |
20150344454 | ANTITUMORAL COMPOUNDS - A compound of general formula (I) wherein A, Y, R | 2015-12-03 |
20150344455 | COMPOUNDS, COMPOSITIONS AND METHODS USEFUL FOR CHOLESTEROL MOBILIZATION - The invention relates to classes of pharmaceutically-active heterocyclic compounds and pharmaceutically acceptable salts, and hydrates thereof, and compositions comprising the same. The invention also relates to methods for treating or preventing a disease or disorder, which comprises administering a therapeutically or prophylactically effective amount a compound described herein. | 2015-12-03 |
20150344456 | NICOTINE SALTS, CO-CRYSTALS, AND SALT CO-CRYSTAL COMPLEXES - The invention provides certain nicotine salts, co-crystals, and salt co-crystals and provides novel polymorphic forms of certain nicotine salts. In particular, nicotine salts with mucic acid, 3,5-dihydroxybenzoic acid, and 2,3-dihydroxybenzoic acid, and crystalline polymorphic forms of nicotine 4-acetamidobenzoate, nicotine gentisate, and nicotine 1-hydroxy-2-naphthoate are described. The invention further provides methods of preparation and characterization of such nicotine salts, co-crystals, and salt co-crystals and polymorphic forms thereof. In addition, tobacco products, including smoking articles, smokeless tobacco products, and electronic smoking articles comprising nicotine salts, co-crystals, and/or salt co-crystals are also provided. | 2015-12-03 |
20150344457 | METHODS OF INHIBITING PRMT5 - Described herein are compounds of Formula (I) useful for inhibiting PRMT5 activity. The planes of Ring AA and Ring BB are between 75° and 105°. Ring AA-M-Ring BB (I) | 2015-12-03 |
20150344458 | Method For Preparing 1-(4-(4-(3,4-Dichloro-2-Fluorophenylamino)-7-Methoxyquinazolin-6-Yloxy)Pi- peridin-1-Yl)Prop-2-En-1-One - The present invention relates to a novel method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one in a simpler process as compared with conventional methods by allowing 4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-ol to react with an N-acyl piperidine derivative in an inert polar protic solvent in the presence of a base. | 2015-12-03 |
20150344459 | 1,4-PYRIDONE BICYCLIC HETEROARYL COMPOUNDS - The present invention relates to 1,4-pyridone bicyclic heteroaryl compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes. | 2015-12-03 |
20150344460 | N-SUBSTITUTED 3,4-BIS (CATECHOL) PYRROLE COMPOUNDS, AND THE PREPARATION AND USE THEREOF IN THE TREATMENT OF CANCER - The present invention relates to a compound of formula (I) in which: —m is an integer from 0 to 3, preferably from 0 to 2; n is an integer from 0 to 3, preferably from 0 to 2; m+n≧1; EAG is an electro-attractive group chosen independently from among a halogen atom, an NO | 2015-12-03 |
20150344461 | HEMI-AMINAL ETHERS AND THIOETHERS OF N-ALKENYL CYCLIC COMPOUNDS - Described herein are hemi-aminal ethers and thioethers of N-alkenyl cyclic compounds that may be produced through a reaction comprising: (A) at least one first reactant represented by a structure (I), wherein X is a functionalized or unfunctionalized C | 2015-12-03 |
20150344462 | IRCINIASTATIN ANALOGUES - The present invention is directed to irciniastatin analogues. Uses of these analogues also described. | 2015-12-03 |
20150344463 | PRMT5 INHIBITORS AND USES THEREOF - Described herein are compounds of Formula (A), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity. Methods of using the compounds for treating PRMT5-mediated disorders are also described. | 2015-12-03 |
20150344464 | PHARMACOKINETICALLY IMPROVED COMPOUNDS - The present invention relates to inhibitors of ROCK1 and ROCK2 and methods of modulating the pharmacokinetic and/or pharmacodynamic properties of such compounds. Also provided are methods of inhibiting ROCK1 and or ROCK2 that are useful for the treatment of disease. | 2015-12-03 |
20150344465 | PYRIDINE COMPOUNDS AS SODIUM CHANNEL BLOCKERS - The invention relates to substituted pyridine compounds of Formula I: (I) or a pharmaceutically acceptable salt, prodrug, or solvate thereof, wherein A | 2015-12-03 |
20150344466 | METHOD FOR CONTROLLING ARTHROPOD PEST - An amide compound represented by formula (I): | 2015-12-03 |
20150344467 | 5- AND 6-MEMBERED HETEROCYCLIC COMPOUNDS - 5- and 6-membered heterocyclic compounds which are inhibitors of phosphodiesterase 10 are described as are processes, pharmaceutical compositions, pharmaceutical preparations and pharmaceutical use of the compounds in the treatment of mammals, including human(s) for central nervous system (CNS) disorders and other disorders which may affect CNS function. Also described is the treatment of neurological, neurodegenerative and psychiatric disorders including but not limited to those comparing cognitive deficits or schizophrenic symptoms. | 2015-12-03 |
20150344468 | 6-SUBSTITUTED-3H-1,3-BENZOTHIAZOL-2-ONE COMPOUNDS AS TARP-GAMMA 8 DEPENDENT AMPA RECEPTOR ANTAGONISTS - A TARP γ8 dependant AMPA receptor antagonist of the formula: | 2015-12-03 |
20150344469 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM - Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity. | 2015-12-03 |
20150344470 | PROCESS FOR THE PREPARATION OF BENZOHETERO [1, 3] DIAZOLE COMPOUNDS DISUBSTITUTED WITH HETEROARYL GROUPS - Process for the preparation of a benzohetero-[1,3]diazole compound disubstituted with brominated heteroaryl groups which comprises reacting at least one dihalogenated benzohetero—[1,3]diazole compound with at least one brominated heteroaryl compound. Said benzohetero [1,3]diazole compound disubstituted with brominated heteroaryl groups can be advantageously used in the synthesis of compounds useful in the construction of solar concentrators (LSCs—“Luminescent Solar Concentrators”). Furthermore, said benzohetero [1,3]diazole compound disubstituted with brominated heteroaryl groups can be advantageously used in the synthesis of photoactive polymers useful in the construction of photovoltaic devices (or solar devices) such as, for example, photovoltaic cells (or solar cells), photovoltaic modules (or solar modules), on both rigid or flexible supports. Furthermore, said benzohetero [1,3]diazole compound disubstituted with brominated heteroaryl groups can be advantageously used as precursor of monomeric units in the synthesis of semiconductor polymers. | 2015-12-03 |
20150344471 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES - The present invention provides compounds of formula I: | 2015-12-03 |
20150344472 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION - Provided are substituted benzaldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation. | 2015-12-03 |
20150344473 | TANK-BINDING KINASE INHIBITOR COMPOUNDS - Compounds having the following formula (I) and methods of their use and preparation are disclosed: | 2015-12-03 |
20150344474 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS - The present invention provides, in part, compounds of Formula I: | 2015-12-03 |
20150344475 | KINASE INHIBITORS - Compounds of formula (I) and pharmaceutically acceptable salts thereof: | 2015-12-03 |
20150344476 | Naphthyridinedione derivatives - The invention relates to compound of the formula (I′) | 2015-12-03 |
20150344477 | HELQUAT DERIVATIVES, PREPARATION THEREOF, AND USE THEREOF AS MEDICAMENTS - The invention provides helquat derivatives of general formula I, wherein substituents R | 2015-12-03 |
20150344478 | PROTEIN KINASE INHIBITORS - The present invention relates to a novel family of inhibitors of protein kinase of formula 1 and process for their production and pharmaceutical compositions thereof. In particular, the present invention relates to inhibitors of the members of the Tec, Src and Btk protein kinase families. | 2015-12-03 |
20150344479 | NOVEL HETEROCYCLIC DERIVATIVES - The invention relates to novel heterocyclic compounds of the formula | 2015-12-03 |
20150344480 | PYRAZOLE SUBSTITUTED IMIDAZOPYRAZINES AS CASEIN KINASE 1 D/E INHIBITORS - The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents. | 2015-12-03 |
20150344481 | NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 D/E INHIBITORS - The invention provides compounds of Formula (I) and pharmaceutically acceptable salts thereof. The compounds of Formula (I) inhibit protein kinase activity thereby making them useful as anticancer agents. | 2015-12-03 |
20150344482 | PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF - A compound with the formula I: | 2015-12-03 |
20150344483 | SUBSTITUTED HETEROARYL ALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION - Provided are substituted heteroaryl aldehydes and derivatives thereof that act as allosteric modulators of hemoglobin, methods and intermediates for their preparation, pharmaceutical compositions comprising the modulators, and methods for their use in treating disorders mediate by hemoglobin and disorders that would benefit from increased tissue oxygenation. | 2015-12-03 |
20150344484 | NOVEL 6-TRIAZOLOPYRIDAZINE SULFANYL BENZOTHIAZOLE DERIVATIVES AS MET INHIBITORS - The disclosure relates to compounds of formula (I): | 2015-12-03 |
20150344485 | BICYCLIC PYRIMIDONE COMPOUNDS AS INHIBITORS OF LP-PLA2 - The present invention relates to novel pyrimido[1,6-a]pyrimidin-6(2H)-one compounds that inhibit Lp-PLA | 2015-12-03 |
20150344486 | PYRIMIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS - The present invention relates to pyrimidine derivatives capable of inhibiting one or more protein kinases. Further aspects relate to pharmaceutical compositions comprising the pyrimidine derivatives and the use thereof in the treatment of proliferative disorders. | 2015-12-03 |
20150344487 | AMINOTETRAHYDROPYRANS AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS FOR THE TREATMENT OF DIABETES - The present invention is directed to novel substituted aminotetrahydropyrans of structural formula I which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved. | 2015-12-03 |
20150344488 | SOLID FORMS OF AN ANTIVIRAL COMPOUND - Amorphous and crystalline solid forms of the anti-HCV compound (1-{3-[6-(9,9-difluoro-7-{2-[5 -(2-methoxycarbonylamino-3-methyl-butyryl)-5-aza-spiro [2 .4]hept-6-yl]-3H-imidazol-4-yl}-9H-fluoren-2-yl)-1H-benzoimidazol-2-yl]-2-aza-bicyclo[2.2.1]heptane-2-carbonyl}-2-methyl-propyl)-carbamic acid methyl ester (Compound I) were prepared and characterized in the solid state: | 2015-12-03 |
20150344489 | OXINDOLE COMPOUNDS CARRYING A CO-BOUND SPIRO SUBSTITUENT AND USE THEREOF FOR TREATING VASOPRESSIN-RELATED DISEASES - The present invention relates to novel substituted oxindole derivatives of formula I | 2015-12-03 |
20150344490 | Heteroaromatic Compounds and their Use as Dopamine D1 Ligands - The present invention provides, in part, compounds of Formula I: | 2015-12-03 |
20150344491 | [1,3] DIOXOLO [4,5-G] QUINOLINE-6(5H)THIONE DERIVATIVES AS INHIBITORS OF THE LATE SV40 FACTOR (LSF) FOR USE IN TREATING CANCER - The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcionoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types. | 2015-12-03 |
20150344492 | MACROCYCLIC BENZOFURAN AND AZABENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C - Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. | 2015-12-03 |
20150344493 | ARTEMISININ COMPOUNDS AND SYNTHESIS AND USE THEREOF - The present disclosure describes artemisinin compounds. The compounds can be synthesized using an Ugi synthesis reaction and can be used in the treatment of cancers, parasitic infections and yeast infections. | 2015-12-03 |
20150344494 | Thienopyranones as Kinase and Epigenetic Inhibitors - The invention relates to methods of treating diseases including but not limited to, cancer non-cancer proliferative disease, sepsis, autoimmune disease, viral infaction, atheroscleosis, Type 1 or 2 diabetes, obesity, inflammatory disease, or Myc-depenent disorder including by modulating biological processes by the inhibition of PI3 kinase and/or bromodomain protein binding to substrates composing the administration of a compound(s) of Formula I-IX (or pharmaceutically acceptable salts thereof) as defined herein. | 2015-12-03 |
20150344495 | PROCESS OF MAKING DIFLUOROTHIENOTHIOPHENE BASED CONJUGATED POLYMERS - A method of producing a monomer wherein the method begins by dissolving 3-fluoro-4,6 dihydrothieno[3,4-b]thiophene in a solvent to create a solution. An initiator is then added to the solution to produce an initiated solution. This is followed by adding a fluorinated chemical to the initiated solution to produce 2,3-difluoro-4,6-dihydrothieno[3,4-b]thiophene. 2,3-difluoro-4,6-dihydrothieno[3,4-b]thiophene is then oxidized with an oxidant to produce 2,3-difluorothieno[3,4-b]thiophene. 2,3-difluorothieno[3,4-b]thiophene is then bromoated to produce 4,6-dibromo-2,3-difluorothieno[2,3-c]thiophene. The final step involves debrominating 4,6-dibromo-2,3-difluorothieno[2,3-c]thiophene and adding an aryl group to produce the monomer | 2015-12-03 |
20150344496 | NOVEL SUBSTITUTED CONDENSED PYRIMIDINE COMPOUNDS - The invention relates to novel substituted condensed pyrimidine compounds of general formula (I) | 2015-12-03 |
20150344497 | PROCESSES OF PREPARING A JAK1 INHIBITOR AND NEW FORMS THERETO - This invention relates to processes for preparing a JAK1 inhibitor having Formula Ia: | 2015-12-03 |
20150344498 | Spiroisoxazoline Compounds Having an Activity Potentiating the Activity of an Antibiotic - The present invention concerns a spiroisoxazoline compound of general formula (I): | 2015-12-03 |
20150344499 | ARYL SULFIDE DERIVATIVES AND ARYL SULFOXIDE DERIVATIVES AS ACARICIDES AND INSECTICIDES - The present invention relates to aryl sulphide and aryl sulphoxide derivatives, to their use as acaricides and insecticides for controlling animal pests and to processes and intermediates for their preparation. The aryl sulphide and aryl sulphoxide derivatives have the general structure (I) | 2015-12-03 |
20150344500 | C2,C6 OXACYCLIC-FUSED THIAZINE DIOXIDE COMPOUNDS AS BACE INHIBITORS, COMPOSITIONS, AND THEIR USE - In its many embodiments, the present invention provides certain C2-ring-substituted iminothiazine compounds, including compounds Formula (I): (structurally represented) or a tautomers thereof, and pharmaceutically acceptable salts of said compounds and, wherein R1, R2, R3, R4, X, ring A, RA, m, -L1-, and RL are as defined herein. The novel compounds of the invention are useful as BACE inhibitors and/or for the treatment and prevention of various pathologies related thereto. Pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other active agents), and methods for their preparation and use, including for the possible treatment of Alzheimer's disease, are also disclosed. | 2015-12-03 |
20150344501 | INHIBITORS OF UDP-GALACTOPYRANOSE MUTASE - Compounds and salts thereof which inhibit microbial growth or attenuate the virulence of pathogenic microorganisms and which inhibit UDP-galactopyranose mutase (UGM). Compounds of the invention include triazolothiadiazines, particularly 3,6,7 -substituted-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazines, and 4-(1H-pyrrol-3-yl) thiazoles, particularly 4-(1,2,5-substituted-1H-pyrrol-3-yl)-2-substituted thiazoles, and salts thereof. Methods for inhibiting growth or attenuating virulence of microbial pathogens including mycobacterium, for example, | 2015-12-03 |
20150344502 | CEPHEM COMPOUND - A compound of the formula: | 2015-12-03 |
20150344503 | INHIBITORS OF FATTY ACID AMIDE HYDROLASE, METHODS OF TREATMENT AND METHODS OF PREPARING SAME - The present invention provides compounds, and pharmaceutical compositions thereof, encompassed by the formulae (I), (II) or (III). | 2015-12-03 |
20150344504 | DIURETHANE (METH)ACRYLATE-SILANE COMPOSITIONS AND ARTICLES INCLUDING THE SAME - Diurethane (meth)acrylate-silane precursor compounds prepared by reacting a primary or secondary aminosilane with a cyclic carbonate to yield a hydroxylalkylene-carbamoylalkylene-alkoxysilanes (referred to as a “hydroxylcarbamoylsilane”), which is reacted with a (meth)acrylated material having isocyanate functionality, either neat or in solvent, and optionally with a catalyst, such as a tin compound. Also described are articles including a substrate, a base (co)polymer layer on a major surface of the substrate, an oxide layer on the base (co)polymer layer; and a protective (co)polymer layer on the oxide layer, the protective (co)polymer layer including the reaction product of at least one diurethane (meth)acrylate-silane precursor compound. The substrate may be a (co)polymer film or an electronic device such as an organic light emitting device, electrophoretic light emitting device, liquid crystal display, thin film transistor, or combination thereof. Methods of making the diurethane (meth)acrylate-silane and their use in composite films and electronic devices are described. | 2015-12-03 |
20150344505 | THERAPEUTIC COMPOSITIONS COMPRISING IMIDAZOLE AND IMIDAZOLIUM COMPOUNDS - Therapeutic compositions comprising substituted imidazole or imidazolium compounds may be used for a number of medical purposes, such as treatment of undesirable conditions or diseases, including disease or conditions related to bone, cancer, and/or pain. | 2015-12-03 |
20150344506 | NOVEL PHOSPHININE OXIDE DERIVATIVE AND PREPARATION METHOD THEREOF - Provided are a novel phosphinine oxide derivative and a preparation method thereof, and more specifically, the phosphinine oxide derivative includes an oxaphosphinine oxide derivative and an azaphosphinine oxide derivative. | 2015-12-03 |
20150344507 | PHOSPHORUS-CONTAINING COMPOUNDS USEFUL FOR MAKING HALOGEN-FREE, IGNITION-RESISTANT POLYMERS - Phosphorus-containing compounds useful for flame retardant epoxy resins are disclosed. The flame retardant epoxy resins may be used to make electrical laminates. This invention is particularly useful in end use applications in which a low bromine or low halogen content is required or desired. | 2015-12-03 |
20150344508 | NITROGEN-RICH MACROCYCLIC LIGANDS, CHELATION COMPLEXES THEREOF, AND PROCESS FOR SELECTIVE CHELATION OF RADIOACTIVE BISMUTH IONS WITH THE LIGANDS - Selective chelation of bismuth radionuclide ions from a mixture including actinium radionuclide ions involves exposing a ligand to an aqueous solution that includes bismuth radionuclide ions and actinium radionuclide ions under conditions whereby the bismuth radionuclide ions selectively chelate to the ligand for form cationic complexes of the bismuth radionuclide ions. and separating the cationic complexes of the bismuth radionuclide ions from the actinium radionuclide ions. The ligands have a structure based on a 12-membered cyclen ring and may include pendant functional groups that can be derivatized with biological targeting vectors for targeted alpha therapy. | 2015-12-03 |
20150344509 | SUBSTITUTED PORPHYRINS - Substituted metalloporphyrin compounds are described, along with pharmaceutical compositions containing the same, and methods of use thereof in protecting cells from oxidant-induced toxicity and pathological conditions such as inflammatory lung disease, neurodegenerative conditions, radiation injury, cancer, diabetes, cardiac conditions and sickle cell disease. Mn(III) porphyrins bearing oxygen atoms within side chains are particularly described. | 2015-12-03 |
20150344510 | PRODUCTION METHOD FOR DODECACARBONYL TRIRUTHENIUM - The present invention is a method for producing dodecacarbonyl triruthenium (DCR) including a process of carbonylating ruthenium chloride with carbon monoxide, in which an amine is added to a reaction system at 0.8 molar equivalent or more with respect to chlorine of the ruthenium chloride and the carbonylation is conducted at a reaction temperature of 50 to 100° C. and a reaction pressure of 0.2 to 0.9 MPa. According to the present invention, it is possible to produce dodecacarbonyl triruthenium having less residual impurity metals without applying a reaction condition of a high pressure. | 2015-12-03 |
20150344511 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR THE TREATMENT OF CANCERS - The present teachings relate to compounds and compositions for treatment of cancers. In some embodiments, the composition comprises a platinum (IV) complex having at least one carboxylate or carbamate ligand. | 2015-12-03 |
20150344512 | METHODS OF PURIFYING STEVIOL GLYCOSIDES AND USES OF THE SAME - A method for purifying steviol glycosides by utilizing a plurality of columns is described. | 2015-12-03 |